1-20 of 23
Kazuhiko Nakagawa
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Nivolumab Retreatment in Non–Small Cell Lung Cancer Patients Who Responded to Prior Immune Checkpoint Inhibitors and Had ICI-Free Intervals (WJOG9616L)

Hiroaki Akamatsu, Shunsuke Teraoka, Shinkichi Takamori, Satoru Miura, Hidetoshi Hayashi, Akito Hata, Yukihiro Toi, Yoshimasa Shiraishi, Nobuaki Mamesaya, Yuki Sato, Naoki Furuya, Jun Oyanagi, Yasuhiro Koh, Toshihiro Misumi, Nobuyuki Yamamoto, Kazuhiko Nakagawa
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (15): 3207–3213.
https://doi.org/10.1158/1078-0432.CCR-22-0602
Published: 02 August 2022
View articletitled, Nivolumab Retreatment in Non–Small Cell Lung Cancer Patients Who Responded to Prior Immune Checkpoint Inhibitors and Had ICI-Free Intervals (WJOG9616L)
Open the PDF for Nivolumab Retreatment in Non–Small Cell Lung Cancer Patients Who Responded to Prior Immune Checkpoint Inhibitors and Had ICI-Free Intervals (WJOG9616L) in another window
Includes: Supplementary data
Journal Articles

A Randomized Phase II Study Comparing Nivolumab with Carboplatin–Pemetrexed for EGFR-Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L)

Hidetoshi Hayashi, Shunichi Sugawara, Yasushi Fukuda, Daichi Fujimoto, Satoru Miura, Keiichi Ota, Yuichi Ozawa, Satoshi Hara, Junko Tanizaki, Koichi Azuma, Shota Omori, Motoko Tachihara, Kazumi Nishino, Akihiro Bessho, Yasutaka Chiba, Koji Haratani, Kazuko Sakai, Kazuto Nishio, Nobuyuki Yamamoto, Kazuhiko Nakagawa
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (5): 893–902.
https://doi.org/10.1158/1078-0432.CCR-21-3194
Published: 01 March 2022
View articletitled, A Randomized Phase II Study Comparing Nivolumab with Carboplatin–Pemetrexed for EGFR-Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L)
Open the PDF for A Randomized Phase II Study Comparing Nivolumab with Carboplatin–Pemetrexed for EGFR-Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L) in another window
Includes: Supplementary data
Journal Articles

Correction: KRAS Inhibitor Resistance in MET-Amplified KRASG12C Non–Small Cell Lung Cancer Induced By RAS- and Non–RAS-Mediated Cell Signaling Mechanisms

Shinichiro Suzuki, Kimio Yonesaka, Takeshi Teramura, Toshiyuki Takehara, Ryoji Kato, Hitomi Sakai, Koji Haratani, Junko Tanizaki, Hisato Kawakami, Hidetoshi Hayashi, Kazuko Sakai, Kazuto Nishio, Kazuhiko Nakagawa
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (2): 428.
https://doi.org/10.1158/1078-0432.CCR-21-4240
Published: 19 January 2022
View articletitled, Correction: KRAS Inhibitor Resistance in MET-Amplified KRASG12C Non–Small Cell Lung Cancer Induced By RAS- and Non–RAS-Mediated Cell Signaling Mechanisms
Open the PDF for Correction: KRAS Inhibitor Resistance in MET-Amplified KRASG12C Non–Small Cell Lung Cancer Induced By RAS- and Non–RAS-Mediated Cell Signaling Mechanisms in another window
Journal Articles

HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

Kimio Yonesaka, Junko Tanizaki, Osamu Maenishi, Koji Haratani, Hisato Kawakami, Kaoru Tanaka, Hidetoshi Hayashi, Kazuko Sakai, Yasutaka Chiba, Asuka Tsuya, Hiroki Goto, Eri Otsuka, Hiroaki Okida, Maki Kobayashi, Ryoto Yoshimoto, Masanori Funabashi, Yuuri Hashimoto, Kenji Hirotani, Takashi Kagari, Kazuto Nishio, Kazuhiko Nakagawa
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (2): 390–403.
https://doi.org/10.1158/1078-0432.CCR-21-3359
Published: 15 January 2022
View articletitled, HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer
Open the PDF for HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

KRAS Inhibitor Resistance in MET-Amplified KRASG12C Non–Small Cell Lung Cancer Induced By RAS- and Non–RAS-Mediated Cell Signaling Mechanisms

Shinichiro Suzuki, Kimio Yonesaka, Takeshi Teramura, Toshiyuki Takehara, Ryoji Kato, Hitomi Sakai, Koji Haratani, Junko Tanizaki, Hisato Kawakami, Hidetoshi Hayashi, Kazuko Sakai, Kazuto Nishio, Kazuhiko Nakagawa
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (20): 5697–5707.
https://doi.org/10.1158/1078-0432.CCR-21-0856
Published: 01 October 2021
View articletitled, KRAS Inhibitor Resistance in MET-Amplified KRASG12C Non–Small Cell Lung Cancer Induced By RAS- and Non–RAS-Mediated Cell Signaling Mechanisms
Open the PDF for KRAS Inhibitor Resistance in MET-Amplified KRASG12C Non–Small Cell Lung Cancer Induced By RAS- and Non–RAS-Mediated Cell Signaling Mechanisms in another window
Includes: Supplementary data
Journal Articles

RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Non–Small Cell Lung Cancer

Kazuhiko Nakagawa, Ernest Nadal, Edward B. Garon, Makoto Nishio, Takashi Seto, Nobuyuki Yamamoto, Keunchil Park, Jin-Yuan Shih, Luis Paz-Ares, Bente Frimodt-Moller, Annamaria H. Zimmermann, Sameera Wijayawardana, Carla Visseren-Grul, Martin Reck, for the RELAY study investigators
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (19): 5258–5271.
https://doi.org/10.1158/1078-0432.CCR-21-0273
Published: 01 October 2021
View articletitled, RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Non–Small Cell Lung Cancer
Open the PDF for RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Non–Small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in EGFR Mutation–Positive Non–Small Cell Lung Cancer

Kohsuke Isomoto, Koji Haratani, Hidetoshi Hayashi, Shigeki Shimizu, Shuta Tomida, Takashi Niwa, Toshihide Yokoyama, Yasushi Fukuda, Yasutaka Chiba, Ryoji Kato, Junko Tanizaki, Kaoru Tanaka, Masayuki Takeda, Takashi Ogura, Tadashi Ishida, Akihiko Ito, Kazuhiko Nakagawa
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (8): 2037–2046.
https://doi.org/10.1158/1078-0432.CCR-19-2027
Published: 15 April 2020
View articletitled, Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in EGFR Mutation–Positive Non–Small Cell Lung Cancer
Open the PDF for Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in EGFR Mutation–Positive Non–Small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Clinical Efficacy and Safety of Nivolumab: Results of a M ulticenter, Op e n-label, Single-a r m, Japanese Phase II study in Mal i gnant Pleural Meso t helioma (MERIT)

Morihito Okada, Takashi Kijima, Keisuke Aoe, Terufumi Kato, Nobukazu Fujimoto, Kazuhiko Nakagawa, Yuichiro Takeda, Toyoaki Hida, Kuninobu Kanai, Fumio Imamura, Satoshi Oizumi, Toshiaki Takahashi, Mitsuhiro Takenoyama, Hiroshi Tanaka, Jun Hirano, Yoshinobu Namba, Yuichiro Ohe
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2019) 25 (18): 5485–5492.
https://doi.org/10.1158/1078-0432.CCR-19-0103
Published: 13 September 2019
View articletitled, Clinical Efficacy and Safety of Nivolumab: Results of a M ulticenter, Op e n-label, Single-a r m, Japanese Phase II study in Mal i gnant Pleural Meso t helioma (MERIT)
Open the PDF for Clinical Efficacy and Safety of Nivolumab: Results of a M ulticenter, Op e n-label, Single-a r m, Japanese Phase II study in Mal i gnant Pleural Meso t helioma (MERIT) in another window
Includes: Supplementary data
Journal Articles

B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity

Kimio Yonesaka, Koji Haratani, Shiki Takamura, Hitomi Sakai, Ryoji Kato, Naoki Takegawa, Takayuki Takahama, Kaoru Tanaka, Hidetoshi Hayashi, Masayuki Takeda, Sigeki Kato, Osamu Maenishi, Kazuko Sakai, Yasutaka Chiba, Takafumi Okabe, Keita Kudo, Yoshikazu Hasegawa, Hiroyasu Kaneda, Michiko Yamato, Kenji Hirotani, Masaaki Miyazawa, Kazuto Nishio, Kazuhiko Nakagawa
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (11): 2653–2664.
https://doi.org/10.1158/1078-0432.CCR-17-2852
Published: 31 May 2018
View articletitled, B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity
Open the PDF for B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity in another window
Includes: Supplementary data
Journal Articles

Randomized Phase II Study of Adjuvant Chemotherapy with Long-term S-1 versus Cisplatin+S-1 in Completely Resected Stage II–IIIA Non–Small Cell Lung Cancer

Yasuo Iwamoto, Tetsuya Mitsudomi, Kazuko Sakai, Takeharu Yamanaka, Hiroshige Yoshioka, Makoto Takahama, Masahiro Yoshimura, Ichiro Yoshino, Masayuki Takeda, Shunichi Sugawara, Tomoya Kawaguchi, Toshiaki Takahashi, Mitsunori Ohta, Yukito Ichinose, Shinji Atagi, Morihito Okada, Hideo Saka, Kazuhiko Nakagawa, Yoichi Nakanishi, Kazuto Nishio
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (23): 5245–5252.
https://doi.org/10.1158/1078-0432.CCR-14-3160
Published: 30 November 2015
View articletitled, Randomized Phase II Study of Adjuvant Chemotherapy with Long-term S-1 versus Cisplatin+S-1 in Completely Resected Stage II–IIIA Non–Small Cell Lung Cancer
Open the PDF for Randomized Phase II Study of Adjuvant Chemotherapy with Long-term S-1 versus Cisplatin+S-1 in Completely Resected Stage II–IIIA Non–Small Cell Lung Cancer in another window
Journal Articles

Tyrosine Phosphoproteomics Identifies Both Codrivers and Cotargeting Strategies for T790M-Related EGFR-TKI Resistance in Non–Small Cell Lung Cancer

Takeshi Yoshida, Guolin Zhang, Matthew A. Smith, Alex S. Lopez, Yun Bai, Jiannong Li, Bin Fang, John Koomen, Bhupendra Rawal, Kate J. Fisher, Ann Y. Chen, Michiko Kitano, Yume Morita, Haruka Yamaguchi, Kiyoko Shibata, Takafumi Okabe, Isamu Okamoto, Kazuhiko Nakagawa, Eric B. Haura
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (15): 4059–4074.
https://doi.org/10.1158/1078-0432.CCR-13-1559
Published: 31 July 2014
View articletitled, Tyrosine Phosphoproteomics Identifies Both Codrivers and Cotargeting Strategies for T790M-Related EGFR-TKI Resistance in Non–Small Cell Lung Cancer
Open the PDF for Tyrosine Phosphoproteomics Identifies Both Codrivers and Cotargeting Strategies for T790M-Related EGFR-TKI Resistance in Non–Small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Activation of HER Family Signaling as a Mechanism of Acquired Resistance to ALK Inhibitors in EML4-ALK–Positive Non–Small Cell Lung Cancer

Junko Tanizaki, Isamu Okamoto, Takafumi Okabe, Kazuko Sakai, Kaoru Tanaka, Hidetoshi Hayashi, Hiroyasu Kaneda, Ken Takezawa, Kiyoko Kuwata, Haruka Yamaguchi, Erina Hatashita, Kazuto Nishio, Kazuhiko Nakagawa
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (22): 6219–6226.
https://doi.org/10.1158/1078-0432.CCR-12-0392
Published: 14 November 2012
View articletitled, Activation of HER Family Signaling as a Mechanism of Acquired Resistance to ALK Inhibitors in EML4-ALK–Positive Non–Small Cell Lung Cancer
Open the PDF for Activation of HER Family Signaling as a Mechanism of Acquired Resistance to ALK Inhibitors in EML4-ALK–Positive Non–Small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Role of ERK-BIM and STAT3-Survivin Signaling Pathways in ALK Inhibitor–Induced Apoptosis in EML4-ALK–Positive Lung Cancer

Ken Takezawa, Isamu Okamoto, Kazuto Nishio, Pasi A. Jänne, Kazuhiko Nakagawa
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (8): 2140–2148.
https://doi.org/10.1158/1078-0432.CCR-10-2798
Published: 14 April 2011
View articletitled, Role of ERK-BIM and STAT3-Survivin Signaling Pathways in ALK Inhibitor–Induced Apoptosis in EML4-ALK–Positive Lung Cancer
Open the PDF for Role of ERK-BIM and STAT3-Survivin Signaling Pathways in ALK Inhibitor–Induced Apoptosis in EML4-ALK–Positive Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Inhibition of Insulin-Like Growth Factor 1 Receptor by CP-751,871 Radiosensitizes Non–Small Cell Lung Cancer Cells

Tsutomu Iwasa, Isamu Okamoto, Minoru Suzuki, Erina Hatashita, Yuki Yamada, Masahiro Fukuoka, Koji Ono, Kazuhiko Nakagawa
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (16): 5117–5125.
https://doi.org/10.1158/1078-0432.CCR-09-0478
Published: 12 August 2009
View articletitled, Inhibition of Insulin-Like Growth Factor 1 Receptor by CP-751,871 Radiosensitizes Non–Small Cell Lung Cancer Cells
Open the PDF for Inhibition of Insulin-Like Growth Factor 1 Receptor by CP-751,871 Radiosensitizes Non–Small Cell Lung Cancer Cells in another window
Includes: Supplementary data
Journal Articles

Phase I Study of YM155, a Novel Survivin Suppressant, in Patients with Advanced Solid Tumors

Taroh Satoh, Isamu Okamoto, Masaki Miyazaki, Ryotaroh Morinaga, Asuka Tsuya, Yoshikazu Hasegawa, Masaaki Terashima, Shinya Ueda, Masahiro Fukuoka, Yutaka Ariyoshi, Toshikazu Saito, Noriyuki Masuda, Hirokazu Watanabe, Tetsuo Taguchi, Toru Kakihara, Yumiko Aoyama, Yohko Hashimoto, Kazuhiko Nakagawa
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (11): 3872–3880.
https://doi.org/10.1158/1078-0432.CCR-08-1946
Published: 01 June 2009
View articletitled, Phase I Study of YM155, a Novel Survivin Suppressant, in Patients with Advanced Solid Tumors
Open the PDF for Phase I Study of YM155, a Novel Survivin Suppressant, in Patients with Advanced Solid Tumors in another window
Journal Articles

Addition of S-1 to the Epidermal Growth Factor Receptor Inhibitor Gefitinib Overcomes Gefitinib Resistance in Non–small cell Lung Cancer Cell Lines with MET Amplification

Takafumi Okabe, Isamu Okamoto, Sayaka Tsukioka, Junji Uchida, Erina Hatashita, Yuki Yamada, Takeshi Yoshida, Kazuto Nishio, Masahiro Fukuoka, Pasi A. Jänne, Kazuhiko Nakagawa
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (3): 907–913.
https://doi.org/10.1158/1078-0432.CCR-08-2251
Published: 02 February 2009
View articletitled, Addition of S-1 to the Epidermal Growth Factor Receptor Inhibitor Gefitinib Overcomes Gefitinib Resistance in Non–small cell Lung Cancer Cell Lines with MET Amplification
Open the PDF for Addition of S-1 to the Epidermal Growth Factor Receptor Inhibitor Gefitinib Overcomes Gefitinib Resistance in Non–small cell Lung Cancer Cell Lines with MET Amplification in another window
Journal Articles

Population Pharmacokinetic/Pharmacodynamic Analyses of Pemetrexed and Neutropenia: Effect of Vitamin Supplementation and Differences between Japanese and Western Patients

Jane E. Latz, Karen Lee Schneck, Kazuhiko Nakagawa, Mary Alice Miller, Chris H. Takimoto
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (1): 346–354.
https://doi.org/10.1158/1078-0432.CCR-08-0791
Published: 31 December 2008
View articletitled, Population Pharmacokinetic/Pharmacodynamic Analyses of Pemetrexed and Neutropenia: Effect of Vitamin Supplementation and Differences between Japanese and Western Patients
Open the PDF for Population Pharmacokinetic/Pharmacodynamic Analyses of Pemetrexed and Neutropenia: Effect of Vitamin Supplementation and Differences between Japanese and Western Patients in another window
Journal Articles

Radiosensitizing Effect of YM155, a Novel Small-Molecule Survivin Suppressant, in Non–Small Cell Lung Cancer Cell Lines

Tsutomu Iwasa, Isamu Okamoto, Minoru Suzuki, Takahito Nakahara, Kentaro Yamanaka, Erina Hatashita, Yuki Yamada, Masahiro Fukuoka, Koji Ono, Kazuhiko Nakagawa
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (20): 6496–6504.
https://doi.org/10.1158/1078-0432.CCR-08-0468
Published: 16 October 2008
View articletitled, Radiosensitizing Effect of YM155, a Novel Small-Molecule Survivin Suppressant, in Non–Small Cell Lung Cancer Cell Lines
Open the PDF for Radiosensitizing Effect of YM155, a Novel Small-Molecule Survivin Suppressant, in Non–Small Cell Lung Cancer Cell Lines in another window
Journal Articles

Phase II Study of Combination Therapy with S-1 and Irinotecan for Advanced Non–Small Cell Lung Cancer: West Japan Thoracic Oncology Group 3505

Isamu Okamoto, Takashi Nishimura, Masaki Miyazaki, Hiroshige Yoshioka, Akihito Kubo, Koji Takeda, Noriyuki Ebi, Shunichi Sugawara, Nobuyuki Katakami, Masahiro Fukuoka, Kazuhiko Nakagawa
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (16): 5250–5254.
https://doi.org/10.1158/1078-0432.CCR-08-0511
Published: 12 August 2008
View articletitled, Phase II Study of Combination Therapy with S-1 and Irinotecan for Advanced Non–Small Cell Lung Cancer: West Japan Thoracic Oncology Group 3505
Open the PDF for Phase II Study of Combination Therapy with S-1 and Irinotecan for Advanced Non–Small Cell Lung Cancer: West Japan Thoracic Oncology Group 3505 in another window
Journal Articles

Efficacy and Safety of Two Doses of Pemetrexed Supplemented with Folic Acid and Vitamin B12 in Previously Treated Patients with Non-Small Cell Lung Cancer

Yuichiro Ohe, Yukito Ichinose, Kazuhiko Nakagawa, Tomohide Tamura, Kaoru Kubota, Nobuyuki Yamamoto, Susumu Adachi, Yoshihiro Nambu, Toshio Fujimoto, Yutaka Nishiwaki, Nagahiro Saijo, Masahiro Fukuoka
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (13): 4206–4212.
https://doi.org/10.1158/1078-0432.CCR-07-5143
Published: 01 July 2008
View articletitled, Efficacy and Safety of Two Doses of Pemetrexed Supplemented with Folic Acid and Vitamin B12 in Previously Treated Patients with Non-Small Cell Lung Cancer
Open the PDF for Efficacy and Safety of Two Doses of Pemetrexed Supplemented with Folic Acid and Vitamin B12 in Previously Treated Patients with Non-Small Cell Lung Cancer in another window